Center for Human Genetics, Bioscientia, Konrad-Adenauer-Str. 17, 55218 Ingelheim, Germany.
J Am Soc Nephrol. 2011 Nov;22(11):2047-56. doi: 10.1681/ASN.2010101080. Epub 2011 Oct 27.
Autosomal dominant polycystic kidney disease (ADPKD) is typically a late-onset disease caused by mutations in PKD1 or PKD2, but about 2% of patients with ADPKD show an early and severe phenotype that can be clinically indistinguishable from autosomal recessive polycystic kidney disease (ARPKD). The high recurrence risk in pedigrees with early and severe PKD strongly suggests a common familial modifying background, but the mechanisms underlying the extensive phenotypic variability observed among affected family members remain unknown. Here, we describe severely affected patients with PKD who carry, in addition to their expected familial germ-line defect, additional mutations in PKD genes, including HNF-1β, which likely aggravate the phenotype. Our findings are consistent with a common pathogenesis and dosage theory for PKD and may propose a general concept for the modification of disease expression in other so-called monogenic disorders.
常染色体显性多囊肾病(ADPKD)通常是一种由 PKD1 或 PKD2 基因突变引起的迟发性疾病,但约 2%的 ADPKD 患者表现出早期和严重的表型,在临床上与常染色体隐性多囊肾病(ARPKD)无法区分。具有早发和严重 PKD 的家系中存在高复发风险,这强烈提示存在共同的家族修饰背景,但导致受影响家庭成员之间观察到广泛表型变异性的机制仍不清楚。在这里,我们描述了患有 PKD 的严重受影响患者,除了预期的家族种系缺陷外,他们还携带 PKD 基因的其他突变,包括 HNF-1β,这可能加重表型。我们的发现与 PKD 的共同发病机制和剂量理论一致,并可能为其他所谓的单基因疾病的疾病表达修饰提出一个通用概念。